Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENPAD: Genotype-guided vs Conventional Clopidogrel in PAD
NCT04619927Phase 4Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel and rivaroxaban in Peripheral Arterial Disease (PAD) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Adverse clinical events related to arterial thrombosis at 24 months. Status: unknown.
02
Drugs
clopidogrelrivaroxaban
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT04619927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619927.